Sign in

    Agilent Technologies Inc (A)

    Q3 2024 Earnings Summary

    Reported on Jan 10, 2025 (After Market Close)
    Pre-Earnings Price$139.99Last close (Aug 21, 2024)
    Post-Earnings Price$145.38Open (Aug 22, 2024)
    Price Change
    $5.39(+3.85%)

    What went well

    • Agilent is seeing signs of recovery in key markets, including China and Pharma, with consumables and services growth indicating increased lab activity. Management expects all areas to improve next year, reflecting a positive outlook.
    • Agilent's instrument book-to-bill ratio remains greater than 1, and instruments performed better than expected in the quarter, suggesting future growth in instrument sales.
    • Management is expecting better performance across all segments in Q4, with guidance reflecting improved revenue and earnings per share, indicating confidence in continued improvement and growth.

    What went wrong

    • Significant declines in key markets, with pharma revenue down 8% and biopharma down low double digits, indicating challenges in the company's largest end markets.
    • Instrument sales decreased by around 14%, reflecting constrained capital spending and continued weakness in demand for capital equipment.
    • China revenue declined 11%, and overproduction in China negatively impacted market investments globally, contributing to softness across several segments.

    Q&A Summary

    1. 2025 Outlook
      Q: What are your expectations for fiscal 2025 growth?
      A: Management anticipates continued steady improvement into fiscal 2025, expecting a return to growth as markets recover. While it's early for specific numbers, they are optimistic about a gradual recovery throughout FY'25, eventually returning to long-term growth rates.

    2. China Sales Recovery
      Q: How is China performing and what's the outlook?
      A: China revenue was down 11%, slightly better than expected, with improvements in pharma and services. Management anticipates mid-single-digit growth in Q4 and expects continued improvement into 2025, supported by increased bidding activity and upcoming stimulus spread over three years.

    3. Instrumentation Growth
      Q: What's the outlook for instrument sales and replacement cycle?
      A: Instrument sales remain challenging but showed improvement; LSAG instruments were down low double digits but better than expected. The book-to-bill ratio was above 1, indicating future growth. Management sees slow but steady improvement, with cautious yet engaged customers suggesting recovery continuing into 2025.

    4. Biopharma Trends and IRA Impact
      Q: How are biopharma customers reacting to IRA impacts?
      A: Large pharma remains cautious due to macro impacts and the Inflation Reduction Act. Despite this, R&D programs are increasing, especially in key modalities like GLP-1. Management expects these trends to normalize, with installed base growth resuming in 2025.

    5. NASD Performance
      Q: What's the outlook for NASD in Q4 and beyond?
      A: NASD performed slightly better than expected; Q3 was in line with expectations. Management expects a $20 million revenue step-up from Q3 to Q4, with orders in-house. Bookings are improving, and they are cautiously optimistic about returning to growth in 2025.

    6. Margin Outlook
      Q: How should we think about margins into 2025?
      A: Management is committed to driving efficiencies, targeting $100 million in annualized savings by end of 2024, benefiting 2025. They expect to drive leveraged earnings next year, aided by volume recovery and strong ACG performance, offsetting merit increases and variable pay resets.

    7. BIOVECTRA Acquisition
      Q: What synergies do you expect with BIOVECTRA?
      A: The BIOVECTRA acquisition enhances capabilities in gene editing, microbial fermentation, and high-potent APIs. It offers synergies like sterile fill-finish and expands capacity in areas like GLP-1 manufacturing. Management sees it as a strategic fit with significant growth potential.

    8. ACG Performance
      Q: Can you provide more context on ACG's dynamics?
      A: ACG performed exceptionally, benefiting from years of investment. Contracts represent nearly 70% of the business, growing double digits. Enterprise service offerings are growing in the mid-teens, helping customers optimize lab operations and improve productivity.

    9. Small vs. Large Molecule
      Q: Why did small molecule perform better than large molecule?
      A: Small molecule business was down mid-single digits, better than expected, especially in Europe. Aging instruments drive replacement needs. Excluding NASD, biopharma was also down mid-single digits, indicating overall stability when adjusted.

    10. Academic and Government
      Q: What trends are you seeing in academia and government?
      A: Revenue declined 11%, mainly due to tough comparisons and funding reallocations in Europe toward defense. Funding remains stable elsewhere, with no major market changes expected.

    11. Chemical and Energy Markets
      Q: How did the chemical and energy market perform?
      A: The segment declined 5% due to overproduction in China affecting global investments. Services and consumables increased by 7%, while instruments decreased by 14%. CapEx spending remains challenged.

    12. Budget Flush Expectations
      Q: Are you expecting a year-end budget flush?
      A: Management is not expecting a significant budget flush. If any occurs, it would likely benefit Q1 of 2025. Their assumption is based on close customer relationships and current funnel visibility.

    Related Publications